SCHEMBL31200525

SCHEMBL31200525

CC(C)(C)OC(=O)N1CCCC(C(=O)Nc2nc3c(Cl)cccc3s2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 1/20 0.49
▸ KMT2A Q03164 7/20 0.49
▸ MEN1 O00255 5/20 0.48
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ PSMD14 O00487 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ CTDSP1 Q9GZU7 1/20 0.47
▸ ADORA2A P29274 1/20 0.45
▸ SENP7 Q9BQF6 1/20 0.45
▸ STS P08842 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31419748 0.90 L3MBTL1 (0.49) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL31200490 0.86 NPC1 (0.50) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL31420264 0.84 KMT2A (0.49) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL31419715 0.82 L3MBTL1 (0.45) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL16239198 0.81 CNR2 (0.65) CNR2KMT2AMEN1NPC1RAB9A
SCHEMBL13256797 0.81 CNR2 (0.65) CNR2KMT2AMEN1NPC1RAB9A
SCHEMBL24071502 0.81 NPC1 (0.62) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL31389076 0.81 NPC1 (0.62) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL25209406 0.81 NPC1 (0.62) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL31389071 0.81 NPC1 (0.62) KMT2AMEN1NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092030-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2025-03-20 — — US disclosed
WO-2024233501-A2 THERAPEUTIC COMPOUNDS ALLOROCK, INC. (US) 2024-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092030-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A PDE2A, GUCY1A1, GCGR CNR2 335/4885KMT2A 1647/4885MEN1 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback